Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Kidney Cancer (Jul 2019)

Posted by Matt Breese on Jul 19, 2019

Find me on:

According to our recent payer coverage analysis for kidney cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for kidney cancer treatments shows that under the pharmacy benefit, about 58% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Kidney Cancer_2Q2019Data snapshot as of Q2 2019

Trends: Currently, Sutent leads the renal cell carcinoma market and may have bolstered its standing with 2017’s label expansion to include use in the adjuvant setting.   

To read the full Reality Check on Kidney Cancer treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing